TrialBMC cancer2014

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Isabelle Borget et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.